StockSelector.com
  Research, Select, & Monitor Wednesday, August 21, 2019 10:48:50 PM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Progenics Pharmaceuticals Inc.$3.86$.195.18%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Progenics Pharmaceuticals Inc. vs Drug Manufacturers/Other

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.




Engaged in the discovery, development, and commercialization of innovative pharmaceuticals for the treatment of many diseases, either directly or indirectly. Directly treating a disease would involve some sort of drug that could attack the infection itself. An indirect treatment may involve a drug that's used to enhance the body's own antibody production so those antibodies can attack the infection themselves. Not only do some of these companies develop drugs for human use, a good number of them also work on animal or plant diseases as well.
 Totals Company Industry
  Sales: $15.6 Mil $98,897.9 Mil
  Market Cap: $312.0 Mil $335,837.3 Mil
  Analysts Recommendation: Strong Buy Buy

 Averages Company Industry
 Growth
  Historic Revenue: 33.5% 171.4%
  Estimated Revenue: 120.0% 256.7%
  Historic Earnings: N/A 37.1%
  Estimated Earnings: N/A 67.3%
  Stock Price (1 Year): (52.2%) (8.3%)
  Cash per Share: 26.3% 35.9%
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: N/A 21.6
  Price-to-Sales: 14.4 N/A
  Price-to-Book: 3.1 1.4
  Dividend Yield: N/A N/A
  Market Cap: $312.0 Mil $12,438.4 Mil
  Operations
  Net Margin: (265.9%) (510.9%)
  Gross Margin: 100.0% 80.4%
  Return on Equity: (.7) (.5)
  Return on Assets: (.4) .0
  Balance Sheet
  Current Ratio: 6.1 7.3
  Quick Ratio: 6.1 7.0
  Cash Ratio: 5.9 6.1
  Debt-to-Equity: .7 2.4
  Interest Coverage: .0 .7
 Technicals
  Relative-Strength Index: 31.8 N/A

 Other companies in Drug Manufacturers/Other Price Market Cap
  Novo Nordisk A\/S  (NVO) $51.82 $122,225.9 Mil
  Allergan plc  (AGN) $161.25 $52,156.3 Mil
  Vertex Pharmaceuticals Inc.  (VRTX) $186.40 $47,734.5 Mil
  UBS AG  (UBS) $10.47 $39,458.9 Mil
  Alexion Pharmaceuticals, Inc.  (ALXN) $114.84 $25,138.6 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.